Clopidogrel Tablet, Film Coated
NDC Package 68071-3319-9

11-digit billing NDC: 68071331909

Package Information

Clopidogrel (clopidogrel bisulfate) tablets is clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke (MI) in patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization. This formulation utilizes a tablet, film coated delivery system. Marketed by Nucare Pharmaceuticals,inc., this product is identified by NDC 68071-3319 and is authorized under FDA application ANDA090540.

Identification & Billing

NDC Package Code
68071-3319-9
Package Description
90 TABLET, FILM COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
68071331909
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Clopidogrel
Non-Proprietary Name
Clopidogrel Bisulfate
Substance Name
Clopidogrel Bisulfate
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke (MI) in patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel tablets should be administered in conjunction with aspirin. managed Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin. and

Regulatory & Marketing

Labeler Name
Nucare Pharmaceuticals,inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA090540
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-17-2012
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68071-3319-9 identifies a specific commercial package of 90 tablet, film coated in 1 bottle of Clopidogrel, a human prescription drug labeled by Nucare Pharmaceuticals,inc.. This tablet, film coated is formulated for oral use and contains clopidogrel bisulfate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Nucare Pharmaceuticals,inc. on May 17, 2012. The current certification is valid through December 31, 2027.

How is this Nucare Pharmaceuticals,inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68071331909. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
68071-3319-9
11-Digit CMS (5-4-2)
68071-3319-09

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.